Aurora Cannabis shareholders have a date circled: December 23, 2026. That is when a virtual special meeting will be held, with a record date of November 18, 2026, to decide whether the company’s recommended combination with Organigram goes ahead — or whether a rival path gains traction.
The Edmonton-based producer, which reported results on November 5 for its second quarter of fiscal 2027 (the period ended September 30, 2026), booked net revenue of C$86.0 million, up from C$78.8 million a year earlier. The standout line item was international medical cannabis, where sales jumped 44% year over year to a record C$61.4 million.
Adjusted EBITDA came in at C$14.0 million — an adjusted metric, not net profit. On the balance sheet, Aurora reported cash, cash equivalents and short-term investments totaling C$133.0 million, alongside zero debt.
Three Ways to Get Paid — With a Catch
Under the agreed Organigram transaction, Aurora investors are being offered C$7.80 per share. The consideration comes in three forms: an all-cash payment of C$7.80, an all-stock alternative of 5.8626 Organigram shares, or a mixed option of C$3.75 in cash plus 3.0431 Organigram shares. Each election is subject to proration.
The stock currently trades at C$7.26, a shade below the headline consideration — a gap that reflects both the time value of waiting and the risk that the deal does not close on the announced terms. Completion is targeted for January 2027 and remains conditional on the necessary approvals, including shareholder and court sign-offs as well as regulatory clearances.
Aurora’s board has unanimously recommended that shareholders back the Organigram agreement and reject Curaleaf’s hostile offer. Curaleaf, for its part, confirmed it has secured all required antitrust clearances in Germany and Canada; its bid is set to expire on December 4, 2026, unless withdrawn or amended.
A Brokerage Downgrade With a Twist
TD Cowen cut Aurora from Buy to Sell on November 5, trimming its price target from C$8.00 to C$7.80. According to media reports, the brokerage advised accepting the Organigram offer, citing the immediate cash component and lower balance-sheet risk attached to the share portion.
Should investors sell immediately? Or is it worth buying Aurora Cannabis?
That view puts the quality of the consideration front and center. For holders weighing their options, it argues in Organigram’s favor — provided its agreed terms and the proposed closing timeline hold.
Growth Story Meets a Softer Earnings Picture
The operational case rests heavily on the international medical franchise. Whether that momentum can underpin the deal’s economics depends on Aurora converting top-line expansion into durable profit. The company narrowed its net loss from continuing operations year over year, yet its adjusted net result fell sharply — a mixed signal that cautions against reading the revenue record as an unqualified win.
That weakness would matter most if the Organigram transaction stalls or falls apart. Investors would then be left valuing Aurora on its standalone earnings power, where the international sales record cuts in its favor while the declining adjusted result pulls the other way.
Aurora scrapped its scheduled investor conference call for November 5 in light of the announced transaction.
What Has to Go Right
The path to closing runs through several gates: the shareholder vote at the December 23 meeting, court approval and regulatory consent. Until those steps are cleared, the promised consideration carries execution risk. And for anyone electing Organigram shares, the value ultimately received will also hinge on how that stock trades after the deal.
Should the agreement stay intact and approvals progress, the takeover value is likely to anchor investment decisions. If completion wobbles, Aurora’s standalone earnings power moves to the fore. The question that matters most is whether the agreed price tag turns into consideration investors can actually bank.
Ad
Aurora Cannabis Stock: Buy or Sell?! New Aurora Cannabis Analysis from November 12 delivers the answer:
The latest Aurora Cannabis figures speak for themselves: Urgent action needed for Aurora Cannabis investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 12.
Aurora Cannabis: Buy or sell? Read more here...
